Introduction: Pará is the second-largest state in Brazil, with 144 municipalities. Health services in Pará that specialize in highly complex oncology are concentrated in large urban centers, such as Belém and Santarém, which affects access to early breast cancer diagnosis. Objectives: To describe the clinical staging at breast carcinoma diagnosis and examine its association with the patients' municipality of residence treated at a referral university hospital in the state of Pará. Methods: This is an epidemiological, descriptive, and retrospective study with a quantitative approach. Inclusion criteria: female, over 18 years old, living in the state of Pará, confirmed diagnosis of breast cancer from 2018 to 2024. The data were extracted from the hospital’s medical records and stored on the secure platform REDCap, organized in a spreadsheet in the Microsoft Excel 2019 software, and analyzed in the Jamovi cloud version 2.6.44. The association between the place of residence (capital vs other municipalities) and the disease stage (initial vs advanced) was evaluated by contingency table and chi-square test. Variables used: age at diagnosis, municipality of residence, clinical staging, and immunohistochemical classification of breast carcinoma in biopsy product. Stage III was adopted as the cut-off point for defining the advanced stage of breast cancer. The study was approved by the Research Ethics Committee with CAAE 55998522.1.0000.5634. Results: Of 584 patients, 99 (16.45%) had the necessary data for analysis. Of these, 50 (50.5%) resided in the capital city of Pará (Belém), and 49 (49.5%) in 33 other municipalities of Pará. Patients ranged in age from 31 to 91 years, with a mean age of 50.7 years. The following frequencies of clinical staging were observed: 6 (0.6%) IA, 24 (24.24%) IIA, 23 (23.23%) IIB, 29 (29.29%) IIIA, 10 (10.10%) IIIB, 2 (2.02%) IIIC, and 5 (5.05%) IV. In this population, 53 (53.5%) and 46 (46.46%) presented, respectively, early and advanced stages of cancer, 25 (47.16%) were from Belém, and 28 (52.8%) were from other municipalities. The distribution of molecular classification at diagnosis was: 7 (7.07%) patients with HER-2 tumor, 32 (32.32%) luminal A or B, 55 (55.55%) triple negative, and 5 (5.05%) had metastasis at diagnosis. The p-value of the contingency table was equal to 0.45. Conclusion: The majority of patients resided in Belém, where the most common clinical stage observed was IIIA. Half of these patients had locally advanced breast cancer. In contrast, among women from outside the capital, stage IIA was the most frequent, and most of the cases were diagnosed at early stages. Furthermore, the findings highlight that this neoplasm affects a wide age range, from young adult women to middle-aged and elderly individuals. The lack of statistical significance (p-value) may be attributed to the disproportionate distribution of histological subtypes—particularly the predominance of triple-negative cases—as well as the limited sample size. This study was relevant in demonstrating the impact of the care provided by this university hospital within the state of Pará.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
